Analysis of Indian Pharmaceutical Market (IPM) – 2024
This data provides insights into the top new introductions (NI) in the Indian Pharmaceutical Market (IPM) for the last 12 months (Dec 2023 – Dec 2024).
Key Highlights:
1. Total Market Impact of New Launches:
• 3151 brands were launched in the last 12 months, generating a total revenue of ₹1096.9 Cr.
• New brands contributed 6.8% to overall IPM growth.
2. Top Performing New Brand – ENHERTU (AstraZeneca)
• ₹57.9 Cr sales, making it the highest-grossing new brand.
• It belongs to the Antineoplastic/Immunomodulator segment, indicating strong growth in cancer-related drugs.
3. Key Companies Driving Growth:
• AstraZeneca: Highest sales from a single new brand (₹57.9 Cr from Enhertu).
• Sun Pharma: Contributed ₹49.9 Cr from 18 new brands, showing a strong pipeline.
• Dr. Reddy’s (DRL): Contributed ₹44.9 Cr from 51 brands, indicating a broad launch strategy.
4. Therapeutic Segments with the Highest Growth:
• Gastrointestinal (₹166.4 Cr from 394 brands) → Leading segment, reflecting demand for digestive health products.
• Antineoplastic/Immunomodulator (₹149.8 Cr from 94 brands) → High growth in oncology and immune-related therapies.
• Vitamins/Minerals/Nutrients (₹126 Cr from 505 brands) → Large volume of launches, showing demand for health supplements.
5. Most New Brands Launched in:
• Cardiac (Heart-related drugs)
• Anti-diabetic (Diabetes management drugs)
• Vitamin/Mineral/Nutrient supplements
Strategic Insights for the Indian Pharma Industry:
✅ Oncology (Cancer) and Immunotherapy are Fast-Growing Segments
• High-value brands like Enhertu (₹57.9 Cr), Spexib (₹11.7 Cr), and Rybbrevant (₹12.8 Cr) show increasing demand.
• Companies investing in oncology drugs (AstraZeneca, Novartis, J&J, DRL, Zydus) are gaining traction.
✅ Cardiac and Diabetes Segments are Expanding Rapidly
• Sybrava Lisy (₹29.8 Cr) and Lyvelsa (₹14.3 Cr) → Strong Cardiac Drug Sales.
• Soliqua Solostar (₹11.8 Cr) → High demand for diabetes management.
✅ Gastrointestinal and Nutrition Segments Have the Highest Volume of New Launches
• While Gastrointestinal drugs have the highest revenue (₹166.4 Cr), the Vitamin/Nutrient segment has the most launches (505 brands), showing rising consumer interest in preventive health.
✅ Sun Pharma, DRL, and Novartis are Market Leaders in New Launches
• Sun Pharma and DRL focus on volume, while AstraZeneca leads in high-value, specialty drugs.
Conclusion:
• Indian pharma is focusing on specialized therapies like oncology and cardiac care.
• Gastrointestinal and nutrition segments are driving volume growth.
• Big players like AstraZeneca, Sun Pharma, DRL, and Novartis are leading new product launches.
